Spiral Therapeutics, a Brisbane, Calif.-based clinical stage pharmaceutical company delivering therapies for hearing loss, held the second closing of its $5.6M Series A financing.
New investors participating in the second closing included Sunghwan Choi and Inveready, which joined the initial investor syndicate led by Savoir Capital and Camden Partners.
This additional funding will support ongoing clinical development in hearing loss, as well as the advancement of discovery programs from our platform.
Launched in early 2016 by Hugo Peris, CEO, Spiral Therapeutics is a clinical stage pharmaceutical company delivering novel therapies for hearing loss. Through the use proprietary therapeutics and drug delivery technologies, the company is building a pipeline of advanced therapies in a field with large unmet needs and no approved therapies. Its lead candidate, LPT99, reached the clinic in December 2018.